Claims
- 1. A non-naturally occurring compound comprising at least one methyl sulfide or methyl sulfoxide moiety, the compound being a substrate for at least one MsrA enzyme and at least one MsrB enzyme, or a pharmaceutically acceptable salt thereof.
- 2. The compound of claim 1, having formula 2, or a pharmaceutically acceptable salt thereof:
- 3. The compound of claim 1, having formula 3, or a pharmaceutically acceptable salt thereof:
- 4. The compound of claim 1, having formula 4, or a pharmaceutically acceptable salt thereof:
- 5. The compound of claim 1, having formula 5, or a pharmaceutically acceptable salt thereof:
- 6. The compound of claim 1, having formula 2a, or a pharmaceutically acceptable salt thereof:
- 7. The compound of claim 1, having formula 3a, or a pharmaceutically acceptable salt thereof.
- 8. The compound of claim 1, having formula 4a, or a pharmaceutically acceptable salt thereof.
- 9. The compound of claim 1, having formula 5a, or a pharmaceutically acceptable salt thereof.
- 10. A non-naturally occurring compound comprising at least one methyl sulfide or methyl sulfoxide moiety, the compound being a substrate for at least one Msr enzyme, said compound having a backbone not based on sulindac (1(Z)-5-fluoro-2-methyl-1[[4-(methylsulfinyl)phenyl)methylene]-1H-indenyl-3-acetic acid).
- 11. The compound of claim 10 having formula 6, or a pharmaceutically acceptable salt thereof:
- 12. The compound of claim 10 having formula 6a, or a pharmaceutically acceptable salt thereof:
- 13. The compound of claim 10 having formula 7, or a pharmaceutically acceptable salt thereof:
- 14. The compound of claim 10 having formula 7a, or a pharmaceutically acceptable salt thereof:
- 15. The compound of claim 10 having formula 8, or a pharmaceutically acceptable salt thereof:
- 16. The compound of claim 10 having formula 8a, or a pharmaceutically acceptable salt thereof.
- 17. The compound of claim 10 having formula 9, or a pharmaceutically acceptable salt thereof:
- 18. The compound of claim 10 having formula 9a, or a pharmaceutically acceptable salt thereof:
- 19. The compound of claim 10 having formula 10, or a pharmaceutically acceptable salt thereof:
- 20. The compound of claim 10 having formula 10a, or a pharmaceutically acceptable salt thereof:
- 21. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- 22. A composition comprising the compound of claim 10 and a pharmaceutically acceptable carrier.
- 23. A method for reducing, preventing or reversing oxidative damage in a cell, the method comprising the steps of:
(a) providing a non-naturally occurring compound comprising at least one methyl sulfide or methyl sulfoxide moiety, the compound being a substrate for at least one Msr enzyme; (b) providing a cell expressing at least one Msr enzyme, said cell comprising or being exposed to reactive oxygen species; and (c) contacting the cell with an amount of the compound sufficient to reduce, prevent, or reverse oxidative damage in the cell by said reactive oxygen species.
- 24. The method of claim 23, wherein the cell is within an animal subject.
- 25. The method of claim 23, wherein the animal subject has a condition or disorder associated with oxidative damage.
- 26. The method of claim 23, wherein the disorder involves degeneration of a nerve cell.
- 27. The method of claim 23, wherein the condition is age-related.
- 28. A method for extending the lifespan of an animal comprising administering to the animal a therapeutically effective amount of a non-naturally occurring compound comprising at least one methyl sulfide or methyl sulfoxide moiety, the compound being a substrate for at least one Msr enzyme.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims the priority of U.S. provisional patent application No. 60/429,269 filed on Nov. 26, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60429269 |
Nov 2002 |
US |